Xeris Biopharma 2025 Q2 Earnings Strong Performance with 87% Net Loss Improvement

Xeris Biopharma (XERS) reported better-than-expected Q2 2025 results, marked by a significant 48.8% year-over-year revenue increase and a substantial 87.2% improvement in net losses. The company raised its full-year revenue guidance to $280–$290 million, reflecting its confidence in sustained growth driven by key product performance and long-term strategic momentum.

Revenue
Xeris Biopharma’s total revenue surged by 48.8% to $71.54 million in Q2 2025 compared to $48.06 million in the same period the prior year. Product revenue, net, stood at $67.71 million, with Recorlev contributing the largest share at $31.44 million—up 135.7% year-over-year. Gvoke and Keveyis also saw revenue increases at $23.47 million and $11.49 million, respectively, while other product revenue added $1.31 million. Royalty, contract, and other revenue reached $3.83 million, marking a 146.7% year-over-year increase.

Earnings/Net Income
The company narrowed its net loss to $1.93 million, or $0.01 per share, in Q2 2025, representing a 87.2% improvement from a $15.01 million loss in Q2 2024. Despite this positive trend, Xeris has incurred losses in nine consecutive years during this period. The reduction in losses was driven by improved revenue growth and cost management, though the company remains in a net loss position.

Price Action
Despite the positive earnings report, the stock price of Xeris Biopharma dipped by 1.86% on the latest trading day. However, it saw a strong surge of 29.67% over the previous full trading week and 38.36% month-to-date, indicating positive investor sentiment amid improved performance metrics.

Post-Earnings Price Action Review
A strategy of buying Xeris Biopharma shares after the revenue growth report and holding for 30 days yielded impressive results over the past three years, achieving a 209.78% return. This outperformed the benchmark return of 51.69% by 158.09%, with a compound annual growth rate (CAGR) of 46.59%. While the strategy was profitable, it came with high volatility of 65.82% and a Sharpe ratio of 0.71, underscoring the risks involved.

CEO Commentary
John Shannon, Chief Executive Officer, highlighted the record $72 million in second-quarter revenue, a 49% year-over-year increase. He attributed the growth to rising patient demand, particularly for Recorlev. Shannon expressed confidence in continuing growth and reiterated the long-term vision, including $750 million in total revenue by 2030, $1 billion in Recorlev net revenue by 2035, and $1–$3 billion peak net revenue for XP-8121.

Guidance
Xeris Biopharma raised its full-year 2025 revenue guidance to $280–$290 million, up from the previous range of $260–$275 million. The company also outlined long-term strategic goals, including $750 million in total revenue by 2030 and $1 billion in Recorlev net revenue by 2035, with XP-8121 targeting $1–$3 billion in peak net revenue.

Additional News
On June 30, 2025, Xeris Biopharma announced record second-quarter financial results, with total revenue increasing 49% year-over-year to $71.5 million. Recorlev revenue grew 136% year-over-year, leading to the decision to raise full-year revenue guidance from $260–$275 million to $280–$290 million. The company provided a detailed long-term outlook during its Analyst and Investor Day in June, outlining strategic goals through 2035. Xeris Biopharma also scheduled a conference call and webcast on August 7, 2025, at 8:30 a.m. Eastern Time to discuss its financial and operational results. Management will also participate in one-on-one meetings at three major investment conferences in September 2025.